EDNRA and pulmonary arterial hypertension: Although bosentan, ambrisentan and macitentan are currently used for the treatment of pulmonary arterial hypertension, only bosentan, a competitive antagonist targeting both ETA and ETB endothelin receptors, is currently licenced for the prevention of DU development.